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E-mail address: simone.badal@uwimona.edu.jm (S. Baa b s t r a c ta r t i c l e i n f oAvailable online 3 June 2017 The organized, tightly regulated signaling relays engaged by the cannabinoid receptors (CBs) and their ligands, G
proteins and other effectors, together constitute the endocannabinoid system (ECS). This system governs many
biological functions including cell proliferation, regulation of ion transport and neuronal messaging. This review
will firstly examine the physiology of the ECS, briefly discussing some anomalies in the relay of the ECS signaling
as these are consequently linked to maladies of global concern including neurological disorders, cardiovascular
disease and cancer. While endogenous ligands are crucial for dispatching messages through the ECS, there are
also commonalities in binding affinities with copious exogenous ligands, both natural and synthetic. Therefore,
this review provides a comparative analysis of both types of exogenous ligands with emphasis on natural prod-
ucts given their putative safer efficacy and the role of Δ9-tetrahydrocannabinol (Δ9-THC) in uncovering the ECS.
Efficacy is congruent to both types of compounds but noteworthy is the effect of a combination therapy to achieve
efficacy without unideal side-effects. An example is Sativex that displayed promise in treating Huntington's dis-
ease (HD) in preclinicalmodels allowing for its transition to current clinical investigation. Despite the in vitro and
preclinical efficacy ofΔ9-THC to treat neurodegenerative ailments, its psychotropic effects limit its clinical appli-
cability to treating feeding disorders. We therefore propose further investigation of other compounds and their
combinations such as the triterpene, α,β-amyrin that exhibited greater binding affinity to CB1 than CB2 and
was more potent than Δ9-THC and the N-alkylamides that exhibited CB2 selective affinity; the latter can be ex-
plored towards peripherally exclusive ECS modulation. The synthetic CB1 antagonist, Rimonabant was pulled
from commercial markets for the treatment of diabetes, however its analogue SR144528 maybe an ideal lead
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The cannabinoid receptors (CBs), their ligands, machinery for ligand
synthesis, metabolism, clearance and transport, along with G proteins
and other effectors, participate in numerous signal relays. Altogether,
these participants are canopied by the endocannabinoid system
(ECS), which is uniquely poised to maintain cellular homeostasis, pro-
viding an avenue for disease preclusion. Endocannobinoids (eCBs), li-
gands of the CBs are synthesized upon demand from membrane
phospholipids (e.g. arachidonylethanolamide/anandamide (AEA) and
2-arachidonoylglycerol (2-AG); Cadas, di Tomaso, & Piomelli, 1997; Di
Marzo et al., 1994; Marrs et al., 2010; Muccioli, 2010; Schmid, Reddy,
Natarajan, & Schmid, 1983) in response to increases in intracellular
Ca+ followed by cellular uptake and rapid clearance. The two
established CBs are CB1, which is highly expressed throughout the
body and CB2, which is mainly localized in immune cells. Activation of
presynaptic CB1 blocks neurotransmitter release through a mixed func-
tion response in which potassium channels are stimulated, while calci-
um channels are inhibited (Howlett et al., 2002). Stimulation of CB1 in
extra-neuronal cells like the liver where immeasurable levels of CB1
exist, results in an elevated expression of acetyl-CoA carboxylase and
fatty acid synthase (Osei-Hyiaman et al., 2005). Meanwhile, CB2 expres-
sion in immune cells participates in many immunosuppressive re-
sponses, such as inhibition of proinflammatory cytokine production
(Maresz et al., 2007). The CBs, together with their associated targets
within the ECS, function in copious signaling relays to modulate physi-
ological andpathophysiological outcomes (appetite, respiration,metab-
olism, inflammation, pain, neurotransmission etc.) in different tissues.
Therefore, dysregulation of these processes can effectuate acute or
chronic diseases such as neurological and cardiovascular disorders,
diabetes and cancers (Insel, Tang, Hahntow, & Michel, 2007).
As such, modulators of this unique system have garnered
significant attention (Novack, 2016; Reuter & Martin, 2016; Sherman
& McRae-Clark, 2016; Zlebnik & Cheer, 2016) in recent times. Further-
more, research on this system over the years have generated clinically
applicable drugs (Cannabinor, Dexanabinol, Rimonabant, Sativex,
Nabilone, and Dronabinol/Marinol), some of which have been with-
drawn from commercial markets due to adverse effects. Despite these
withdrawals, the promised efficacy of the ECS modulators continues to
drive research towards regulatory approval of lead molecules, both
natural and synthetic in origin.
Natural product research towards the development of drugs, also
termed Pharmacognosy, dates back to the time of Hippocrates (470–
350 BCE). It was the common practice then to use natural products,
which at the time were primarily from plants, to achieve healing and
also to protect against diseases (American Herbal Pharmacopoeia,
2013). As a result, the field of drug discovery developed from natural
isolates. Moreover, Δ9-THC from the Cannabis sativa plant alluded to
the eCBs, CBs and subsequently the ECS. Natural products continue to
be ideal screening agents in the arena of drug development; indeed
more than 50% of traditional drugs are either directly of natural origin
or are templates of natural sources (Newman & Cragg, 2012). Further-
more, 30–50% of traditional medicines are believed to act through
G protein coupled receptor proteins, of which CBs are members
(Bjenning, Al-Shamma, Thomsen, Leonard, & Behan, 2004; Dahl &
Sylte, 2005; Doggrell, 2004; Kroeze, Sheffler, & Roth, 2003). It is the be-
lief of many that natural products do provide safer outcomes with less
associated side-effects, however, research has shown that such notion
tends to be more anecdotal than evidence based (Meier & Lappas,
2015). The father of toxicology, Roman physician Paracelsus believedthat all things are poisonous, with the distinction between safety and ef-
ficacy residing in the dose (Borzelleca, 2000). It is unclear whether or
not there are safer effects attributable to natural products' use, however
it is evident that their chemistry continue to provide clues towards the
treatment of diseases especially through novel targets.
This review presents an overview of the ECS, factors that cause its
dysregulation, the use of natural and synthetic products towards ECS-
associated morbidities and future perspectives. The emphasis will be
on natural products' modulation of the ECS and whether based on a
comprehensive overview, they provide better alternatives.
2. The physiology of the ECS
2.1. ECS signaling
CBs belong to the rhodopsin type family within the GPCRs andwhile
structural elucidations for the CBs are still ongoing, a review by Kenakin
and Miller (2010) outlines the conformational changes experienced by
this family of GPCRs upon ligand binding and the modulation of alloste-
ric and orthosteric ligands to functionally identify novel drug leads.
Within the rhodopsin family, three regions were postulated to partici-
pate in their activation, i) Trp6.50, at the bottom of the major intra-he-
lical ligand-binding pocket, ii) Tyr7.53, postulated to unite the bottomof
TM7 and helix 8 at the cytosolic surface of the lipid bilayer, and iii)
Arg3.50 at the cytosolic locale of TM3, where it possibly couples with
the G protein. Together, these regions are believed to manipulate the
rhodopsin type GPCRs' response to ligand binding and their conforma-
tional change to the cytosolic interface that aid or thwart coupling to
specific effectors in order to transduce intracellular signaling.
A common feature of the GPCR signaling pathway is initiation by a
ligand (hormones, neurotransmitters, inflammatory mediators and
other bioactive molecules) that binds to a GPCR protein (Cabrera-Vera
et al., 2003). Ligand-mediated activation of the GPCR in turn stimulates
G proteins that are comprised of three subunits: α, β and γ and such
stimulation prompts the replacement of GDP with GTP in the Gα sub-
unit as shown in Fig. 1. The Gα-GTP complex is then dissociated from
theGβγ subunits, an action that enables bothmolecular entities to trans-
duce numerous signals through their various effectors (Cabrera-Vera et
al., 2003) as shown in Fig. 2. In addition, CB1 or CB2 ligand signal trans-
ductions are also achieved through β-arrestin couplings that have been
shown to participate in receptor desensitization internalization,
resensitization, and down-regulation (Daigle, Kearn, & Mackie, 2008;
Jin et al., 1999; Nguyen et al., 2012; Raehal & Bohn, 2014; Sim,
Hampson, Deadwyler, & Childers, 1996).
GPCRs are usually named after their ligands and so this section will
examine the signaling cascade involved in message relay initiated by
the cannabinoid/CB pockets. The CB itself is coined after the plant, Can-
nabis sativa that led to its discovery (DiMarzo&Maccarrone, 2008). The
structural identification of the plant's principal ingredient Δ9-THC
(Gaoni & Mechoulam, 1964) and subsequently the bioactivity of its l-
stereoisomer (Mechoulam, Braun, & Gaoni, 1967) together acted as a
springboard for identifying to date 113 cannabinoids in the Cannabis
sativa plant (Aizpurua-Olaizola et al., 2016), including eCBs and endog-
enous arachidonic acid derivatives, in addition to the synthesis of ap-
proximately 180 Δ9-THC analogues (Banister et al., 2015; Howlett et
al., 2002; Rosati et al., 2014). Therefore, the rhodopsin CBs are regulated
by three categories of ligands, eCBs, phytocannabinoids (phyCBs) and
synthetic cannabinoids (synCBs). PhyCBs are referred to here as any
natural product from the Cannabis sativa or other plants that either di-
rectly (modulate CBs, G proteins, eCBs or β-arrestins) or indirectly
Fig. 1. GPCRmediated signal transductions. This figure offers a basic pictorial outline of the differences between an inactivated G protein (Gαβγwhere Gα binds GDP and the entire unit
binds to GPCR) and the activated G protein (Gα-GDP is replaced with GTP and Gα dissociates from Gβγ) which then is able to activate various effectors. The figure is not meant to depict
appropriate ratios of the proteins to the cell itself. Key: EL—endogenous ligand.(modulate the enzymatic systems that synthesize, metabolize, trans-
port and clear the eCBs including fatty acid amide hydrolase (FAAH),
monoacylglycerol lipase (MAGL), diacylglycerol lipase (DAGL) α,β hy-
drolase 6 and 12 (ABHD6 and ABHD12)) interact with the ECS and/or
share chemical similarity with the eCBs.
There are to date, two main identified types of CBs, CB1 that is pri-
marily localized in the brain (although it is also found in lungs, liver
and kidneys) and CB2 that is mostly expressed in peripheral tissues, in
particular, the immune and skeletal systems (Ameri, 1999). Very recent
X-ray crystal structures (Fig. 3 shows identified amino acid residues that
function in CB1's regulation) have become available for CB1 (Hua et al.,
2016; Shao et al., 2016) after considerable attempts at preparing CB ho-
mology models (Feng et al., 2014; Liu, Patel, & Doerksen, 2014; Shim,
Welsh, & Howlett, 2003). Both CBs couple to the G protein effector, Gio
and their signal transductions are complex and only summarized here
where the following observations are not necessarily similar in all tis-
sues expressing CBs. CB1 couples to Gs G proteins although Gi coupling
is the canonical coupling for CB1. More comprehensive reviews on the
ECS signaling cascade (Dalton, Bass, Van Horn, & Howlett, 2009;
Howlett and Shim, 2000-2013; Howlett et al., 2004; Maccarrone et al.,
2015) exist for consultation. Ligand induced CBs/Gio associations typi-
cally result in inhibition of the cyclase activity of AC usually the AC 1,
3, 5, 6 and 8 isoforms, while CBs/Gβγ associations activate AC 2, 4 and
7 isoforms (Rhee, Bayewitch, Avidor-Reiss, Levy, & Vogel, 1998). Recep-
tor dimerization has also been observed to participate in AC activation
when GPCR dopamine D2 and CB1 are simultaneously activated (Glass
& Felder, 1997; Kearn, Blake-Palmer, Daniel, Mackie, & Glass, 2005).
This dimerization has also been linked to CB1/Gα coupling while CB1/
Gq/11 coupling leads to an increase in intracellular calcium ions
(Lauckner, Hille, & Mackie, 2005) and Phospholipase C (PLC) activation(Piiper, Stryjek-Kaminska, Klengel, & Zeuzem, 1997). Meanwhile, CB1/
Gβγ coupling modulates phosphorylation of different ion channels, as
calcium channels are inhibited (Gebremedhin, Lange, Campbell,
Hillard, &Harder, 1999;Mackie &Hille, 1992)whereas potassium chan-
nels are activated (Mackie, Lai,Westenbroek, &Mitchell, 1995). CB1/Giα
coupling also participates in the phosphorylation of ion channels, how-
ever, this is mediated through inhibiting AC (1, 3, 5, 6, and 8 isoforms),
an outcome that stimulates protein kinase A. In addition, CB1/Gio cou-
pling i) induces all three families of multifunctional mitogen-activated
protein kinases, including p44/42 (Davis, Ronesi, & Lovinger, 2003;
Wartmann, Campbell, Subramanian, Burstein, & Davis, 1995), p38 ki-
nase (Derkinderen, Ledent, Parmentier, & Girault, 2001; Liu et al.,
2000), and JUN-terminal kinase (Liu et al., 2000; Rueda, Galve-Roperh,
Haro, & Guzman, 2000); ii) activates the phosphatidylinositol-3-kinase
(PI3K) and MAPK pathways directly (Gomez Del Pulgar, De Ceballos,
Guzman, & Velasco, 2002) and independently (Asimaki & Mangoura,
2011) and iii) activates calcineurin (Stefano et al., 1997). The CB1/G pro-
tein coupling specificities remain to be fully elucidated with regards to
NOS stimulation as information is steered to CB1/ligand coupling
(Stefano et al., 1997). More recently, CB1 was shown to activate extra-
cellular regulated kinases also known as ERK1/2 and neuronal induction
in primary neurons from chick embryo telencephalon through lipid
rafts (Asimaki & Mangoura, 2011).
Unlike CB1, the elucidation ofmany signal transduction pathways for
CB2 are yet to be discovered. Current CB2 mediated effects include CB2/
Gi/o trafficking that participates in the inhibition of cAMP (Rhee et al.,
1998) and the activation of MAPK, p42/44 family (Bouaboula et al.,
1996). However, CB2 agonists failed to activate PKB/Akt in HL60 cells,
suggesting that a PI3Kmechanismmay not be engaged by CB2 receptors
(Gomez Del Pulgar et al., 2002). In contrast, the expression of the
Fig. 2. Ligand induced intracellular signal transductions by cannabinoid receptors associated with G proteins. When a ligand, such as an endocannabinoid, synthetic derivative or natural
product binds to either CB1 or CB2 exhibiting agonistic effects, various signaling cascades can ensue. These pathways to date are largely dependent on the isoform of G protein that couples
to the CB. In the event, Giα binds to CB1 and one of many effectors can become activated, the outcome of which is largely due to tissue specificity and ligand/CB pocket association not
described in this figure. Currently, the cumulative targets modulated by this association are i) inactivation of AC (1, 3, 5, 6 & 8 isoforms) and activation of ii) PI3K, iii) MAPK (p38, p42/
44), iv) ERK1/2, v) calcineurin and vi) various ion channels via protein kinase A induction. In addition, under this CB/Giα, coupling cAMP can induce other targets and these include,
Trk-A, Rap1 and Braf and FAK. Ligand association with CB1/Gβγ complex can result in the activation of the AC 2, 4 and 7 isoforms and Ca+ increases concentration and the
phosphorylation of various ion channels. Activation of these AC (2, 4 & 7) isoforms can also ensue from CB1/D2 dimerization. The CB1/Gβγ coupling has also been shown to activate PLC
and NOS. The dimerization between CB1 and D2 have also been linked to the CB1/Gq/11 coupling which can result in an increase in PLC activation and an increase in Ca+ ions. Together,
the careful regulation of these target molecules determines the fate of the cell. Not shown in this figure are the effects of β-arrestins which can also couple with the CBs initiating G
protein independent signaling such as the activation of p42/44MAPK cascade or Src kinases in addition to CB desensitization and internalization.nuclear protein that functions as a transcriptional regulator, Krox-24
also known as EGR-1 (early growth response protein 1) was stimulated
by CB2 receptors in HL60 promyelocytes (Bouaboula et al., 1996).
2.2. Endocannabinoids, cues for cannabinoid modulation
Documentation of Δ9-THC as a ligand of the CBs paved the way for
identifying eCBs and elucidating their mechanisms of action. The varied
bindingmodalities by these eCBs as either orthosteric (primary unmod-
ulated) agonists, inverse agonists or antagonists contribute to ECSmedi-
ated physiological outcomes. The first eCB, anandamide, also referred to
as N-arachidonoylethanolamine or AEA was discovered in 1992 by
Devane et al. (1992). This discovery wasmade only a year after the elu-
cidation of CB1 (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990)
and before the elucidation of CB2 (Munro, Thomas, & Abu-Shaar,
1993). The second eCB, 2-AG, was discovered three years later
(Mechoulamet al., 1995; Sugiura et al., 1995). Since then, other putative
eCB targets have been identified (Johns et al., 2007;Overton et al., 2006)
but the biosynthesis, metabolism, transport and function of eCBs have
been primarily focused on AEA and 2-AG.
The production of these eCBs occurswhen there is an elevation in in-
tracellular Ca2+ subsequent to either neuron depolarization or activa-
tion of metabotropic Gq/11-coupled receptors. AEA is a fatty acid
derivative neurotransmitter that is synthesized from N-arachidonoyl
phosphatidylethanolamine by many pathways, derived from the non-
oxidative metabolism of arachidonic acid (Cadas et al., 1997; Di Marzo
et al., 1994; Schmid et al., 1983) and discussed in more detail in
Bosier, Muccioli, Hermans, & Lambert (2010), Pacher, Batkai, & Kunos
(2006), and Pertwee (2009). In contrast, 2-AG is produced from activi-
ties of diacylglycerol lipase (DAGL) and PLC and different pathwaysare engaged in its in vitro versus in vivo synthesis (Savinainen, Saario,
& Laitinen, 2012). Once taken up into the cell, AEA's metabolism is
achieved by FAAH while MAGL is primarily observed to catalyze 2-AG
although ABHD6 (Marrs et al., 2010), ABHD12 and FAAH (Blankman,
Simon, & Cravatt, 2007) also participate in the hydrolysis of 2-AG. The
inducible form of COX, COX2 also plays a role in oxidizing AEA and 2-
AG (Kozak et al., 2002).
Both eCBs are agonists of CB1 and CB2 receptors, however, AEA ex-
hibits low CB1 efficacy and an even lower efficacy towards CB2. Mean-
while, 2-AG binds to the CBs with reduced affinity but is fully effective
at both CBs (Gonsiorek et al., 2000). The eCBs are released upon de-
mand, bind to the coupledCB/Gprotein complex inducing signaling cas-
cades as observed in Fig. 2, prior to being rapidly cleared from the
extracellular matrix. Their transport mechanism however remains to
be fully unraveled although a putative eCB transporter and heat shock
proteins (Hsp70s) are implicated in AEA transport (Gerdeman, Ronesi,
& Lovinger, 2002;Maccarrone et al., 2000), while fatty acid binding pro-
teins are implicated in the transport of both eCBs (Kaczocha, Glaser, &
Deutsch, 2009; Oddi et al., 2009).
In the CNS, signaling of the eCB/CB1/G protein complex is to date
largely achieved using retrograde synaptic relay (Chevaleyre,
Takahashi, & Castillo, 2006; Wilson & Nicoll, 2002). As retrograde mes-
sengers, eCBs are released from depolarized postsynaptic neurons in a
calcium-dependent manner as they reversely inhibit periglomerular
cells by way of glutamatergic neurons that are presynaptic to these
cells. Therefore, retrograde signaling induced inhibition of the
periglomerular cells controls the cell's GABA release, which in turn con-
trols primary cell activity (Thomas, Ze-Jun, Edward, & Paul, 2016). Find-
ings show that retrograde signaling by the eCBs may be important for
treating feeding disorders (Pertwee, 2006b) as elucidations indicate
that some mechanisms are involved in CB1's participation in increasing
food intake in mice via elevating odor detection. These include a reduc-
tion in the excitatory drive of the olfactory cortex areas in the main ol-
factory bulb (Soria-Gomez, Bellocchio, & Marsicano, 2014). Further, it
is believed that the eCBs' involvement in the inhibition of
periglomerular cells provides novel insights into their potential role to
mitigate substance abuse (Thomas et al., 2016). Endocannabinoids
also participate in regulating cell migration and the production of cyto-
kines and chemokineswhich play a role inmaintaining homeostatic im-
mune function (Cabral, Ferreira, & Jamerson, 2015). Conversely,
elevated levels of the eCB, AEA, have been associated with stunted em-
bryonic development, foetal loss and pregnancy failure (Maccarrone,
2009; Maccarrone et al., 2001). Altogether, supporting evidence exists
which underlies eCBs as neuromodulators and immunomodulators
and their inhibition towards enhanced fertility. These translate to anti-
nociceptive action (Kaczocha et al., 2014), anxiolytic-like properties
(Marco et al., 2015), antidepressant activity (Trezza & Campolongo,
2013), anti-tumour efficacy (Picardi, Ciaglia, Proto, & Pisanti, 2014),
and the lowering of blood pressure in hypertensive experimental
models (Batkai, Pacher, Jarai, Wagner, & Kunos, 2004). The continuous
elucidation of the pharmacological properties of the eCBs underscores
their value in restoring cellular homeostasis and treating certain dis-
eases while taking into account their adverse effects.3. ECS signaling gone awry and its restoration
3.1. Factors that affect ECS and its signaling relay
Di Marzo, Stella, and Zimmer (2015) discuss at length in a review,
factors that are associated with a dysregulated ECS highlighting age,
neurological diseases and cancer and so will only be briefly mentioned
here in addition tomutationswithin the CBs caused by genetic or epige-
netic factors (Gyombolai, Toth, Timar, Turu, & Hunyady, 2015).
Clinical and pre-clinical evidence exist that demonstrate the impact
ageing has on varied aspects of the ECS signal relay. Firstly, a reduction
in CB1 gene expression levelswas observed in the extrapyramidal struc-
tures of aged rats compared to their younger counterparts (Berrendero
et al., 1998; Rodriguez de Fonseca, Ramos, Bonnin, & Fernandez-Ruiz,
1993). Furthermore, the CB1 binding affinity was also impacted in
these preclinicalmodels andother research confirms this effect in a clin-
ical setting (Rodriguez de Fonseca et al., 1993). In humans, the expres-
sion of key genes in the ECS that regulate CB's orthosteric ligands and
their inactivating enzymes were impacted with maturation of brain
function (Long, Lind,Webster, &Weickert, 2012). CB/G protein coupling
was also affected by ageing in the limbic forebrain of mouse models
(Wang, Liu, Harvey-White, Zimmer, & Kunos, 2003).
Classical (e.g.Alzheimer's disease (AD), Parkinson's disease (PD) and
amyotrophiclateral sclerosis (ALS)) or inflammatory associated (e.g.
multiple sclerosis (MS) andHIV-associated dementia) degenerative dis-
orders of the CNSwhichmay occur concomitantlywith or independent-
ly of ageing (Stella, 2010) exhibit similar etiologies, neuroinflammation,
excitotoxicity, deregulation of intercellular communication, mitochon-
drial dysfunction and disruption of brain tissue homeostasis. Induced
signaling by CB1 and CB2 are important to Ca2+ homeostasis, trophic
support, mitochondrial activity (Ranieri, Laezza, Bifulco, Marasco, &
Malfitano, 2016), the generation, specification and maturation of neu-
rons in addition to brainmaturation (Skaper &Walsh, 1998). Preclinical
evidence supports an association between inflammation and ECS de-
rived neurological disease (Hegde, Nagarkatti, & Nagarkatti, 2010) in
mice that underwent experimental allergic encephalomyelitis (EAE)
or multiple sclerosis. Other findings (Maresz et al., 2007) demonstrated
the role of low levels of CB2 in non-CNS cells to prevent and control neu-
roinflammation and its accompanied disorders. Consequently,
disrupted CB1/2 signaling may play a role in degenerative disorders of
the CNS.The mammalian target of Rapamycin (mTOR) is a target molecule
associated with cancer and it is one of the downstream signaling effec-
tors of CB1 and leptin through PI3K activation.mTOR enables both cellu-
lar nutrient sensing and energy homeostasis through the ERK/MAPK–
Akt pathway, in addition to the expression of c-myc and cyclin D1 that
contributes to cell growth and survival and the transcription of a num-
ber of hypoxia-inducible genes including vascular endothelial growth
factor (VEGF) and platelet derived growth factor (PDGF) (Rini &
Atkins, 2009). These genes have implications for mitogenesis, perme-
ability, vascular tone and the production of vasoactive molecules
(Zachary, 1998). Therefore, the mTOR complex participates in a wide
array of biological functions including angiogenesis, synaptic plasticity
and cognitive function, and usage of the mTOR inhibitor, Rapamycin,
blocked mTOR mediated angiogenesis (Sekiguchi et al., 2012) and con-
ferred cellular cytoprotectivity (Busquets-Garcia et al., 2013;
Rubinsztein, Marino, & Kroemer, 2011). Interestingly, antagonism of
CB1 was shown to inhibit autophagy in a mTOR mediated manner
(Hiebel, Kromm, Stark, & Behl, 2014), a phenomenon possibly related
to ageing and certain neurodegenerative disorders such as ALS and PD
(Centonze, Finazzi-Agro, Bernardi, & Maccarrone, 2007).
Finally, CB mutations have been associated with anomalies in
the ECS signal relay that are concomitant to certain diseases like certain
neurodegenerative disorders, discussed more by Maccarrone, Bernardi,
Agrò, & Centonze (2011). The review highlights the general role choles-
terol plays with respect to the CBs which can either be through a direct
impact of the CB conformation states via CRAC, cholesterol recognition
amino acid sequence consensus in helix 7 on the CBs or indirectly alter-
ing the physiochemical properties of the bilayer as shown in Fig. 3.More
definitive mutations such as single-, double- and/or triple-alanine mu-
tations in the highly conserved DRYmotif within the CB1 have been re-
cently found to display either bias towards G proteins or β-arrestins
(Gyombolai et al., 2015). Single alaninemutations decreased Go protein
activation and enhanced basal β-arrestin 2 recruitment while a double
mutant (CB1-D3.49A/R3.50A) augmented β-arrestin 1 and 2 recruit-
ment but decreased G-protein activation. CB2 mutations have been
linked to oncogenic effects as CB2 gene transforming mechanisms
using ligands or retroviral insertions resulted in altered cellular migra-
tion and a reduction in neutrophilic development in addition to aber-
rant expression of CB2 in human myeloid cell lines respectively
(Alberich Jorda et al., 2004).3.2. Synthetic CB ligands
The identification of the natural isolate, Δ9-THC from the Cannabis
sativa plant not only led to the identification and isolation of other nat-
urally derived phyCBs (natural products from the Cannabis sativa or
other plants that modulate the ECS) but to synCBs, synthetic products
that also modulate the ECS. These synCBs are structurally classified as
either classical, non-classical, aminoalkylindoles, eicosanoids or others
and are represented in Table 1. Classical ligands are analogues of the
Δ9-THC isolate and these tend to behave as agonists of the CBs showing
minimal selectivity but in some cases showing increased affinity. One
such example is HU-210 whose increased affinity to the CB is believed
to be a result of replacing the pentyl side chain on Δ9-THC with a
dimethylheptyl group (Griffin et al., 1997; Ross et al., 1999; Sanchez et
al., 2001). HU-210 was shown to participate in maximal CB1 coupling
to the G proteins, Gi and Go compared to the eCB, AEA and the phyCB,
Δ9-THC in addition to CB1 receptor-catalyzed activation of Gi (Glass &
Felder, 1997). Moreover, activation of the Gi/o complex achieved by a
synthetic peptide fragment from the juxtamembrane C-terminal region
of the CB1 receptor independently activated both [35S] guanosine 5′-O-
(3-thio)triphosphate (GTPγS) binding to G proteins and inhibition of
adenylate cyclase (Howlett, Song, Berglund, Wilken, & Pigg, 1998;
Mukhopadhyay, Cowsik, Lynn, Welsh, & Howlett, 1999), therefore indi-
cating the role this domain plays in Gi/o activation.
Fig. 3. X-ray crystal structure of human CB1 cannabinoid receptor (rendered in gold; PDB ID: 5U09) bound to inverse agonist ligand taranabant (spheres). Cholesterol interaction motif
“CRAC” is highlighted in orange. Ligand binding has disrupted the LYS192-ASP366 salt bridge interactions. A closer look at the taranabant (B; rendered in grey) binding site and the
top docked pose of the inverse agonist ligand Rimonabant (C; rendered in olive green) reveal similar ring stacking interactions with PHE200/TRP356 and PHE170.A characteristic of non-classical CB ligands is an A-ring accompanied
by an aryl C-3 side chain bicyclic structure also termed, AC bicyclic and
ACD-tricyclic structures that have an opening in the D rings. The CB bi-
cyclic analog, CP55940, is a CB full agonist that is 45 times more potent
than Δ9-THC, has parallel affinity for both CB1 and CB2 receptors and is
highly potent in vivo (Rinaldi-Carmona et al., 1996). In 2005, the first
CB1 allosteric sitewas identified (Price et al., 2005) and a synthetic com-
pound, Org27569was shown to enhance CB agonist binding (specifical-
ly CP55940), inhibit G protein-dependent agonist signaling using in
vitro models expressing CB1 receptor (Ahn, Mahmoud, & Kendall,
2012) and participate in β-arrestin CB1 biased signaling (Ahn,
Mahmoud, Shim, & Kendall, 2013). Org27569 demonstrated preclinical
hypophagic activity that has implications for weight loss (Ding et al.,
2014) and propelled the synthesis of other allosteric compounds
with parallel binding affinities (Qiao et al., 2016). Allosteric modulation
welcomes a novel approach to the manipulation of the ECS for thera-
peutic benefit. Recent research identified R-(+)-WIN55212, an
aminoalkylindole that has a high affinity for both CBs with a slightly en-
hanced affinity for CB2, a property also displayed by the other
aminoalkylindoles, JWH-015 and L-768242 (Showalter, Compton,
Martin, & Abood, 1996). R-(+)-WIN55212 also maximally activates
CB1 receptor-catalyzed activation of Gi, while sub-maximally (at
around 70%) engages in CB1 stimulation of Go (Glass & Northup,
1999). Methylation of AEA results in methanandamide being 9-
fold more specific than AEA for CB1 (Showalter et al., 1996). Over-
all, agonists of the CBs are involved in cognition, memory, anxiety,
control of appetite, emesis, motor behavior, sensory, autonomic
and neuroendocrine responses, immune responses and inflamma-
tory effects (Svíženská, Dubový, & Šulcová, 2008), liver injury and
hepatocellular carcinoma (Sathyapalan et al., 2016) and so the re-
verse conditions are anticipated in the presence of their antago-
nists and these are highlighted in Fig. 4. CB1's primary locale in
the hypothalamus underscores its potential value in treating feed-
ing disorders since the hypothalamus plays a role in feeding regu-
lation and is connected to the mesolimbic dopamine pathway, the
so called ‘reward’ system.Antagonists of the CB1 receptors are therefore believed to be impor-
tant to the weight loss paradigm (Black, 2004) and drug (nicotine and
Δ9-THC) cessation is important to weight gain (Filozof, Fernandez
Pinilla, & Fernandez-Cruz, 2004; Schindler et al., 2016). After a decade
of attempts to synthesize the first CB antagonist, first through isoforms
of Δ9-THC, Rinaldi-Carmona et al. (1994) reported the successful syn-
thesis of SR141716A also called Rimonabant, a potent CB1 antagonist,
that propelled the synthesis of other CB antagonists. Analogues of
Rimonabant, AM251 and AM281 also block CB1 receptor-mediated ef-
fects while SR144528 is a CB2 antagonist (Rinaldi-Carmona et al.,
1994, 1998). CBs active states can be induced by their respective ligands
or by spontaneous shifting between inactive to active states (Ortega-
Gutierrez & Lopez-Rodriguez, 2005). Rimonabant, the inverse agonist,
binds to the CB1 and interaction is thought to exist through hydrogen
bonding between the carbonyl group of Rimonabant and the Lys192
residue of the CB1 receptor, shown in Fig. 3. This bond stabilizes the
Lys192-Asp366 salt bridge in CB1 helices 3 and 6, believed to be specific
to the inactive CB1 state (Lange & Kruse, 2005; McAllister et al., 2003).
Rimonabant, through direct stacking of its 2,4-dichlorophenyl ring to
the Trp279/Phe200/Trp356 residues (on CB1) on one end and the
para-chlorophenyl ring (on Rimonabant) to the Tyr275/Trp255/
Phe278 (on CB1) on the other end, binds within the transmembrane-
3-4-5-6 aromatic microdomain of the CB1 (Fan et al., 2009; Lange &
Kruse, 2005). These binding interactionswith CB1 seem to be important
to Rimonabant's clinical efficacy to treat diabetes (Muccioli & Lambert,
2005) and a proposedmechanism is through increased insulin sensitiv-
ity in an age-dependent manner (Lipina et al., 2016) and oxidation of
fatty acids in muscles and the liver (Patel & Pathak, 2007). Current pre-
clinical and in vitro findings suggest that Rimonabant through its CB1
antagonism treats non-alcoholic fatty liver disease (NAFLD) by blocking
fatty liver metabolism (Sathyapalan et al., 2016). More recently, the ef-
fects of Rimonabant to minimize drug dependence of nicotine and Δ9-
THC in squirrel monkeys were mimicked by a neutral antagonist,
AM4113 (Schindler et al., 2016). Rimonabant as an antagonist/inverse
agonist of the CB1 is much concretized and its implications in weight
loss, anti-diabetes and reduced drug dependency are established. Also
Table 1
Synthetic CB ligands, their structures, binding affinities and bioactivities.
Synthetic cannabinoids Binding type/CB Bioactivity Reference
Classical
HU-210
Agonist/CB1, CB2 Analgesic, neuroprotective Guhring et al. (2001), Lax, Esquiva, Altavilla, and
Cuenca (2014)
Nabilone
Agonist/CB1, CB2 Analgesic, antiemetic,
anti-inflammatory
Conti, Costa, Colleoni, Parolaro, and Giagnoni
(2002), Darmani, Janoyan, Crim, and Ramirez
(2007)
Δ8-THC
Agonist/CB1,CB2 Antiemetic, orexigenic Avraham et al. (2004), Webster and Sarna
(2007)
Desacetyl-L-nantradol
Agonist/CB1,CB2 Analgesic Pertwee (2005)
JWH-133
Agonist/CB2 Anti-cancer Chakravarti et al. (2014)
Agonist/CB2 Unknown Chakravarti et al. (2014)
Table 1 (continued)





Hanuš et al. (1999)
L-759633
Agonist/CB2 Analgesic Ross et al. (1999)
L-759656
Agonist/CB2 Analgesic Howlett et al. (2002)
Non-classical
CP55940
Agonist/non-selective Anti-nociceptive, antiemetic, Darmani et al. (2003), Pugh, Mason, Combs, and
Welch (1997)
CP55244
Agonist/CB1 Anti-nociceptive Little, Compton, Johnson, Melvin, and Martin
(1988)
(continued on next page)
Table 1 (continued)
Synthetic cannabinoids Binding type/CB Bioactivity Reference
CP47497
Agonist/CB1 Analgesic, anticonvulsive, motor
depressive





Hypophagic Ding et al. (2014)
Aminoalkylindoles
R-(+)-WIN55212
Agonist/CB1 Analgesic, anti-inflammatory Herzberg, Eliav, Bennett, and Kopin (1997),




Lombard, Nagarkatti, and Nagarkatti (2007)
L-768242 (GW405833)
Agonist/CB2 Analgesic, anti-inflammatory Clayton, Marshall, Bountra, and O'Shaughnessy
(2002)
Table 1 (continued)
Synthetic cannabinoids Binding type/CB Bioactivity Reference
Eicosanoids
Methanandamide
Agonist/CB1 Analgesic, antiemetic, orexigenic,
anti-proliferation, anti-migration





Guindon and Hohmann (2011), Rutkowska and
Fereniec-Goltbiewska (2006)
Arachidonylcyclopropylamide (ACPA)




Antagonist/CB1 Anti-obesity, smoking cessation,
neuropsychiatric effects
Boekholdt and Peters (2010), Boyd and
Fremming (2005), Carai, Colombo, and Gessa
(2005)
SR144528
Inverse agonist/CB2 Anti-nociceptive Clayton et al. (2002), Portier et al. (1999)
(continued on next page)
Table 1 (continued)
Synthetic cannabinoids Binding type/CB Bioactivity Reference
SR147778 (Surinabant)
Antagonist/CB1 Anorectic, smoking cessation;
suppression of alcohol
preference
Lallemand and De Witte (2006), Lamota et al.
(2008), Rinaldi-Carmona et al. (1998)
AM251
Inverse agonist/CB1 Antidepressant, anorectic McLaughlin et al. (2003), Shearman et al. (2003)
AM281
Antagonist/CB1 Improves cognitive deficits Vaseghi, Rabbani, and Hajhashemi (2012)recently, CB1's modulation has been implicated in olfaction, a process in-
volved in food intake, visual perception and social interaction and a pro-
posed putative marker for schizophrenia and autism (Hu, 2016).
Rimonabant was also shown to participate in pharmacological
and behavioral effects independent of CB1 receptor activation as it is an
agonist/antagonist of the transient receptor potential vanilloid receptor
1 (TRPV1) (Hu, 2016). Therefore, Rimonabant exerted olfactory discrimi-
nation deficit by modulating both CB1 and TRPV1 receptors.
Direct interactions with the CBs are not the only pathways to partic-
ipate in disease amelioration. Research on the CB2 antagonist,
Rimonabant analogue, SR144528 is believed to exhibit anti-obesity
and anti-diabetic properties achieved in part through its inhibition of
CB1/CB2 induction of orexin A/orexin 1 receptor (OXR1). OXR1 is a
GPCR protein that regulates feeding disorder and like CB1 is expressed
in the lateral hypothalamus. In a heterologous model that co-expressed
both GPCRs, CB1 was shown to induce orexin-mediated mitogen-
activated protein kinase activation more than 100 fold, an effect that
was attenuated by the CB1 antagonist/inverse agonist, SR141716/
Rimonabant (Hilairet, Bouaboula, Carriere, Le Fur, & Casellas, 2003). Fur-
thermore, cannabinoid-opioid cross-modulation has been implicated in
antinociception, hypothermia, sedation and reward (Wang, Zhang, et
al., 2016). Recent studies have shown that a CB1 antagonist delayedlong-term hyperexcitability after brain injury by i) inhibiting long-
term up-regulation of CB1 receptors in the hippocampus, ii) exhibiting
long-term potentiation of dynorphin, iii) no impact on the up-regula-
tion of κOR (another rhodopsin GPCR) in hippocampus and iv) reverse
the overexpression of mGluR5 in the late stage of brain injury (Wang,
Zhang, et al., 2016). SR141716 also participated in the enhancement of
ischemia-induced glutamate release after prolonged alcohol withdraw-
al (Zheng, Wu, Dong, Ding, & Song, 2015).
The research on the synthetic CB antagonists although promising are
associated with unideal convoys and so many have been pulled from
commercial markets and clinical trials. Rimonabant was approved by
the European Union in 2006 to treat diabetes but was discontinued
from commercial markets and clinical trials two years later because of
serious risk of psychiatric disorders (Sanofi-aventis, 2008). Taranabant
(MK-0364) and otenabant (CP-945,598) were both discontinued in
phase III clinical trials for treating obesity due to the risk/reward ratio
(Aronne et al., 2010; Pfizer, 2008; Pharmacodia, 2008) and Surinabant
(SR147778) was discontinued from clinical trials for smoking cessation
(R & D Focus Drug News, 2008). Some therefore believe that the current
thrust towards tackling these adverse effects is to restrict binding asso-
ciations to peripheral CB1 and so limit the crossing of the blood brain
barrier (BBB) by small molecules (Chorvat, 2013).
Table 2
Natural CB ligands, their structures, binding affinities and bioactivities.

















Ligresti et al. (2006),
Pertwee (2008)
Cannabinol









tumour models b increase neural stem
cell viability
Appendino et al. (2008),
Izzo et al. (2012), Ligresti et








Borrelli et al. (2013), Granja






Anti-inflammatory Bolognini et al. (2010)
CB1
independent
Anticonvulsant Amada, Yamasaki, Williams,
and Whalley (2013), Hill et
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Antagonist, CB1 Analgesic, antimicrobial Dhopeshwarkar et al.
(2011), Lim, Sung, Ji, and
Mao (2003), Mitscher et al.
(1978)
Sanguinarine
Antagonist, CB1 Anticancer, apoptosis inducer,
improved gut peristalsis
Das and Khanna (1997),
Dhopeshwarkar et al.





Immunomodulatory Guiotto et al. (2008),






Guiotto et al. (2008),
Raduner et al. (2006)
Nonclassical (cannabinomimetic derivative)
Haplosamates A (R = O, SO3Na)
Agonist/CB1/CB2 Unknown Pereira, Pfeifer, Grigliatti,
and Andersen (2009)
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Anti-inflammatory, anti-nociceptive da Silva et al. (2011)
β-Caryophyllene

















Braida, Limonta, Pegorini, et
al. (2007), Capasso, Borrelli,
Cascio, et al. (2008)
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Korte et al. (2009), Patel,


















Nicolussi et al. (2014)
3.3. Natural products as ligands of the ECS, better efficacy than synCBs
or not?
It has been highlighted that a natural product, Δ9-THC paved the
way for understanding the role of CBs and their eCBs. Of the over 100
phyCBs present in Cannabis sativa, the major constituents within the
plant are Δ9-THC, cannabidiol (CBD) and cannabinol (CBN) (Russo,
2011). UnlikeΔ9-THC (Cumella et al., 2012), CBD and CBN are non-psy-
chotropic phytocannabinoids (Pertwee, 2006a) and exhibit poorer
binding affinities to the CBs. However, findings thus far have uncovered
enhanced efficacy (considering the reduced psychotropic effects) when
using the combination therapy, CBD and Δ9-THC which will be the pri-
mary focus of this section. Δ9-THC binds with similar affinities to CB1
and CB2 receptors at nanomolar concentrations. It behaves like a CB1 re-
ceptor partial agonist and CB1/CB2 receptor antagonist (Pertwee, 2008).
Under the trademarkMarinol,Δ9-THC is used to treat anorexic associat-
ed disorders in patients with AIDS and nausea related conditions in pa-
tients on certain chemotherapies (Hazekamp & Grotenhermen, 2010).
The lack of euphoric accompaniment by Marinol could be due to
its dose, while the other trademark, Nabilone is used to treat chemo-
therapy induced nausea and vomiting. Δ8-THC has similar affinities
for CB1 and CB2 receptors akin to Δ9-THC (Paronis, Nikas, Shukla, &
Makriyannis, 2012). Other classically derived phyCBs are Cannabigerol
(CBG), Cannabichromene (CBC), Tetrahydrocannabivarin (THCV),
Cannabidivarin (CBDV) and these and more along with modulatory ef-
fects on the ECS are outlined in Table 2.
PhyCBs have been shown to exhibit promising efficacy towards
many conditions including, i) CNS disorders (Hill, Williams, Whalley,
& Stephens, 2012); ii) convulsions (Hill et al., 2010); iii) neurodegener-
ation (Gilbert, Kim, Waataja, & Thayer, 2007; Zani, Braida, Capurro, &
Sala, 2007), iv) epilepsy (Cunha et al., 1980; dos Santos, Hallak, Leite,
Zuardi, & Crippa, 2015); v) sleep disorders (Murillo-Rodríguez
(Murillo-Rodriguez, Millan-Aldaco, Palomero-Rivero, Mechoulam, &
Drucker-Colin, 2006) and vi) inflammation (Costa et al., 2004).
The structural similarities shared between Δ9-THC and the eCBs,
AEA and 2-AG explain the ability of this phyCB to activate CB1 and
CB2. Δ9-THC binds to both receptors (CB1 and CB2) with higher affinity
(nM range) than its corresponding (+)-cis (6aS, 10aS) enantiomer (+)-
Δ9-THC) and with equal or greater affinity than other phyCBs, (−)-Δ8-
THC,Δ9-THCV, CBD, CBG and CBN. However,Δ9-THC exhibits lower af-
finity and efficacy than synCBs, HU-210, CP55940 and R-(+)-
WIN55212 (Pertwee, 2008) and the eCBs (Pertwee, 2008). AdditionalFig. 4. Synopsis of research approach based on current research findings when treating variou
participate in ECS compromise, while a cause and effect relationship with the latter requires f
occurring mainly through CB agonism, with various phenotypic properties. These include: an
pressure effects. Stimulants of the ECS system have been associated with the treatment of H
have been associated with treating weight loss (which has implications for treating cardiovascto its partial agonism of the CBs, Δ9-THC activated G proteins by 44%
(specifically for the interaction of CB2 receptors with Gi) and CB1-cata-
lyzed Gi by 56% (Glass & Northup, 1999). These observed effects were
weaker than the synCB, HU-210 and the eCB, AEA. Akin to the eCBs,
Δ9-THC can inhibit ongoing neurotransmitter release through neuronal
presynaptic CB1 receptors (Pertwee & Ross, 2002). This is believed to
account for many of the Δ9-THC mediated CB1 effects such as
analgesia, muscle relaxation, anti-emesis or appetite stimulation as
well as psychotropic properties (Pertwee, 2000). Furthermore, Δ9-
THC antinociceptive effects were shown to be mediated through
β-arrestin-2 as β-arrestin-2-KO mice failed to desensitize their CB1 re-
ceptors after Δ9-THC stimulus and therefore were more sensitive to
Δ9-THC (Breivogel, Lambert, Gerfin, Huffman, & Razdan, 2008;
Nguyen et al., 2012). Δ9-THC is not as selective for CB1 (Kreitzer,
2005; Vaughan & Christie, 2005), as its (CB1) mediated activation has
been linked to the activation of other neurotransmitters like dopamine
and acetylcholine (Gardner, 2005; Nagai et al., 2006; Pertwee & Ross,
2002; Pisanu, Acquas, Fenu, & Di Chiara, 2006; Pistis et al., 2002),
which is believed to restrict its clinical applicability to treating anorexia,
nausea and vomiting. Although CB1 commonly facilitates inhibition of
continuous neuronal transmitter release (on which it is located), it's
(CB1) activation as shown prior, sometimes results in an opposite effect.
These mixed effects that Δ9-THC participates in in vivo is a possible rea-
son why this phyCB exhibits both excitant and depressant effects as it
has been shown to demonstrate anticonvulsant properties in certain
in vivo models but proconvulsant activities in others (Berrendero &
Maldonado, 2002; Braida, Limonta, Malabarba, Zani, & Sala, 2007;
Chiu, Olsen, Borys, Karler, & Turkanis, 1979; Colasanti, Lindamood, &
Craig, 1982; Dewey, 1986; Fish, Consroe, & Fox, 1983; Patel & Hillard,
2006; Schramm-Sapyta et al., 2007; Turkanis & Karler, 1981; Wallace,
Blair, Falenski, Martin, & DeLorenzo, 2003). Therefore, perhaps combi-
nation therapies of inhibitors of these other neurotransmitters (acetyl-
choline and dopamine), further discussed (Babitha, Sahila, Bandaru,
Nayarisseri, & Sureshkumar, 2015; Čolović, Krstić, Lazarević-Pašti,
Bondžić, & Vasić, 2013; Wang, Shen, et al., 2016) with Δ9-THC can be
explored. One such example is rivastigmine (Gawel et al., 2016). It
should be noted however, that a comprehensive overview of the func-
tion, production and associated targets of these neurotransmitters is
critical when deciding ideal combinations. For example, the loss of do-
paminergic neurons in the substantia nigra par compacta has been im-
plicated in the onset of certain neurodegenerative diseases like PD,
and so some studies demonstrate that the stimulation of dopamines disease conditions that ensue from ECS compromise. Factors like age and inflammation
urther delineation. Research findings thus far have linked stimulation of the ECS system,
xiolytic, antidepressant, antinociceptive, antiemetic, anti-tumour and reduction in blood
D, PD, ALS and cancer. Meanwhile, antagonists of the ECS, occurring mainly through CB,
ular morbidities), diabetes and drug cessation.
confers neuroprotective properties (Ablat et al., 2016). On the other
hand, overstimulation of dopamine participates in drug dependence
(Dackis & Gold, 1985). Hence, further delineation is needed to identify
appropriate combinations with Δ9-THC that could generate optimum
efficacy with minimal side-effects. In addition to the mixed stimulato-
ry-inhibitory effects of Δ9-THC on CB1 mediated neurotransmission re-
lease/inhibition, the phyCB can inhibit central neurotransmission. As
Δ9-THC exhibits lower affinity and efficacy compared to some phyCBs
and eCBs, its particular demonstrable bioactivity is believed to be
governed by the CBs' density and their coupling efficiencies (Childers,
2006; Pertwee, 2006b). Hence, in certain cells/tissues, Δ9-THC may
not exhibit agonistic traits but block the efficacy of other ligands that
demonstrate higher binding affinities (Patel & Hillard, 2006; Sim et al.,
1996). The partial agonistic traits of Δ9-THC can therefore be clinically
applicable to disease conditions that result in an upregulation of the
CBs in a cell/tissue specific manner. Such upregulation is thought to in-
crease the selectivity and efficacy of partial CB agonists like Δ9-THC.
The other well researched phyCB is CBD, a key cannabinoid constitu-
ent in Cannabis sativa that represents up to 40% of cannabis extracts
(Grlic, 1976). However, unlike Δ9-THC, it is well tolerated and does not
present with psychoactive properties; CBD's bioactivities are thought to
be a priori its innate chemical structure, specifically its hydroxyl groups
(Mechoulam, Parker, &Gallily, 2002) rather than its ligand-mediated sig-
nal transduction effect. CBD's bioactivities are more defined around its
neuroprotective effects although there is preclinical evidence of its
anti-tumorigenic property (McAllister, Christian, Horowitz, Garcia, &
Desprez, 2007). This is believed to occur because of one or more of the
following; its ability to impede adenosine uptake (Liou et al., 2008),
down-regulate the enzymes FAAH and 5-lipoxygenase (Capasso,
Borrelli, Aviello, et al., 2008;Massi et al., 2008), or bind both transient re-
ceptor potential vanilloid 1 (TRPV1) (Iannotti et al., 2014) and 5-hy-
droxytryptamine (serotonin) receptor 1A (5-HT1A) receptors (Russo,
Burnett, Hall, & Parker, 2005). The neuroprotective properties of CBD
are thought to be independent of the ECS (De Filippis et al., 2010) except
in select conditions (Bisogno et al., 2001; Castillo, Tolon, Fernandez-Ruiz,
Romero, &Martinez-Orgado, 2010; De Filippis et al., 2008). Nonetheless,
emerging research shows that despite the low affinity CBD displays for
the CBs, this phyCB exhibits possible noncompetitive binding to CB1
and CB2, possibly as an inverse agonist at certain concentrations below
which it binds to both (CB1 and CB2) orthosteric sites (Lunn et al.,
2006; MacLennan, Reynen, Kwan, Bonhaus, & Martin, 1998; Thomas et
al., 2007). Further, CBD also demonstrates antagonistic effects on CB1 ag-
onists, CP55940 (Petitet, Jeantaud, Reibaud, Imperato, & Dubroeucq,
1998) and R-(+)-WIN55212 (Pertwee & Ross, 2002) in various in vitro
and preclinical models.
CBD's neuroprotective effects are thought to be because of i) its abil-
ity to restore the normal balance between oxidative events and anti-
oxidant endogenous mechanisms (Fernandez-Ruiz, Garcia, Sagredo,
Gomez-Ruiz, & de Lago, 2010), often dysregulated in neurodegenerative
disorders; ii) the upregulation of endogenous antioxidant enzymes to
control oxidative stress, specifically transcription factor nuclear factor-
erythroid 2-related Factor 2 (Nrf-2) induced signaling; iii) its anti-
inflammatory activity via the canonical pathway (Walter et al., 2003),
limiting ATP induced-increases in intracellular Ca+ levels andNOproduc-
tion in microglial cells (Martin-Moreno et al., 2011) and other mecha-
nisms discussed further (Fernandez-Ruiz et al., 2013). While CBD has
also shown evidence of neuroprotection via an ECS independent pathway
(Abood, Rizvi, Sallapudi, &McAllister, 2001; Gilbert et al., 2007), themod-
ulation of CB1 also plays a role in this paradigm as observed in in vitro
(Abood et al., 2001; Gilbert et al., 2007) and preclinical (Chen & Buck,
2000; El-Remessy et al., 2003; van der Stelt et al., 2001; Zani et al.,
2007) models. Furthermore, other phyCBs, Δ9-THC and THCV's agonistic
properties of the CB2 have also been implicated in preclinical neuropro-
tection (Garcia et al., 2011; Tourino, Zimmer, & Valverde, 2010).
The promising neuroprotective potential of CBD has propelled its el-
evation of research from basic science to clinical, especially since itseems to attract less psychoactive side-effects than its Δ9-THC counter-
part. There is compelling preclinical evidence supporting the efficacy of
CBD's neuroprotection against neonatal ischemic insults (Alvarez et al.,
2008; Castillo et al., 2010; Fernandez-Ruiz et al., 2010; Lafuente et al.,
2011). Additionally, CBDwas shown tominimize necrotic and apoptotic
damage brought about by glucose-oxygen deprivation in newbornmice
using the newborn hypoxic-ischemic brain damage (NHIBD) model
(Castillo et al., 2010). The mechanism of action is believed to occur
through CBD's normalization of glutamate and cytokines in addition to
the inhibition of iNOS and COX-2. Co-incubation with a CB2 antagonist
abolished the observed effects which strongly suggests the role of CBs
in CBD's observed neuroprotection cascade in newborns (Castillo et
al., 2010).
CBD's application in combination with other phyCBs has revealed
ideal synergism. CBD combined with Δ9-THC, akin to the drug Sativex
was shown to be effective in treating Huntington's disease in preclinical
models (rats lesioned with 3-nitropropionic acid) (Sagredo, Ramos,
Decio, Mechoulam, & Fernandez-Ruiz, 2007; Sagredo et al., 2011) and
believed to occur via CB1 and CB2 dependent pathways. Another
model that utilized malonate induced lesions in rats seemed to engage
a CB2 pathway only as CBD alone was ineffective while other CB2 ago-
nists were effective (Sagredo et al., 2009). The combination therapy of
CBD and Δ9-THC towards treating HD has thus far exhibited promising
efficacy which has already transitioned them to clinical trials
(Fernandez-Ruiz et al., 2013). PD is another neurodegenerative disorder
that seems to be mitigated by the action of CBD by CB1 independent
mechanisms (Garcia et al., 2011; Garcia-Arencibia et al., 2007;
Lastres-Becker, Molina-Holgado, Ramos, Mechoulam, & Fernandez-Ruiz,
2005) as CB1 is associated with reduced motor activity as evidenced
from clinical studies (Fernandez-Ruiz, 2009). Therefore, it is believed
that the activation of CB2 and not CB1 might be more ideal for
treating ECS associated diseases. However, such an angle could po-
tentially preclude opportunities to treat CB1 associated morbidities.
Hence, like Sativex, perhaps other combinations with CBD could be
explored e.g. CBD with CB1 inhibitors like the phyCB, THCV that
showed preclinical evidence of treating PD (Garcia et al., 2011) and
CBD with α,β-amyrin, a potent CB1 triterpenoid phyCB (da Silva et
al., 2011) discussed more below.
Currently, Sativex, a 1:1 combination of Δ9-THC and CBD is used to
treat neuropathic pain, spasticity, overactive bladder and other symp-
toms of multiple sclerosis (Rahn & Hohmann, 2009; Russo, 2008).
Many phyCBs are undergoing clinical trials for various ailments as
outlined in a review (Hazekamp & Grotenhermen, 2010), this includes
tetrahydrocannabinol, Δ9-THC, CBD, dronabinol, marinol, nabilone,
The challenge that exists when utilizing exogenous CB1 agonists is
the onset of psychosomatic symptoms and recently, overactive CB1
was shown to participate in type 2 diabetic nephropathy (Jourdan et
al., 2014). So the question lies in how to strike a balance, maintaining
the efficacy of the phyCBs while blocking the side-effects. So far we
have explored a possible mechanism that accounts for the side-effects
of Δ9-THC which could be the upregulation of certain neurotransmit-
ters, acetylcholine and dopamine upon CB1 activation. Indeed, the par-
tial agonism that Δ9-THC seems to exert is thought to reduce its
efficacy especially when there is normal to suboptimal levels of CB1.
On the other hand, this type of binding is believed to hold promise in in-
stances where CB1 and CB2 activation are elevated and particularly lo-
calized to certain tissues as binding affinity to the phyCB would be
more restricted to those tissues/cells with elevated CB expression. This
phenomenon is not uncommon as the cytochrome P450 (CYP)
CYP1B1 enzyme whose presence is usually induced by the activation
of the aryl hydrocarbon signal transduction pathway is believed to
hold promise in treating certain cancers. CYP1B1's presence is often
times elevated in cancerous tissues like prostate relative to normal
neighbouring tissue (Yang et al., 2008) and so chemotherapy pro-
drugs that aremetabolized only by CYP1B1 are believed to hold promise
as target-specific anticancer drugs (Roos & Bolt, 2005). Although
CYP1B1 is an enzyme and CB1 is a receptor, the principle remains as the
upregulation of CBs can be a positive angle for utilizing Δ9-THC, the po-
tential side-effects of this phyCB can be mitigated using combination
therapies as discussed prior. A polypharmacology approach is not un-
common when treating diseases especially since the lock and key ap-
proach towards disease amelioration seem to produce less than ideal
outcomes (Medina-Franco, Giulianotti, Welmaker, & Houghten, 2013).
Currently, we know that ligand binding of CB1 can participate in nu-
merous outcomes as shown in Figs. 2 and 4 and even much more re-
mains to be elucidated. Many reviews have been published on the
effects of natural products on the CB1 at the in vitro and preclinical levels
(Di Marzo & Piscitelli, 2015; Gertsch, Pertwee, & Di Marzo, 2010;
McAllister, Soroceanu, & Desprez, 2015; Sharma, Sadek, Goyal, Sinha,
& Kamal, 2015) and so will not be reiterated here. These reviews have
highlighted the modulatory effects of phyCBs that either exhibit direct
or indirect impact on the ECS. Overall, many alkaloids, alkylamide deriv-
atives, terpenes, polyphenols, polyacetylene and various fatty acids and
fatty acid amides, from terrestrial andmarine plant sources have shown
in vitro and/or preclinical evidence of ECS modulation towards efficacy.
Table 2 in this reviewhighlights those phyCBs that have exhibited CB se-
lectivity and/or potent direct or indirect ECSmodulation, of these, note-
worthy ones are discussed below.
We previously examined in detail the effects of 2 classical phyCBs
that have and continue to be researched for efficacy. However, other
phyCBs also hold promise. Non-classical CBs, fatty acid derivatives, N-
alkylamides from the Echinacea spp. that show some structural similarity
to the eCB, AEA, demonstrate preferred binding affinity to the CB2
resulting in elevated levels of intracellular Ca+ ions (Gertsch, Raduner,
& Altmann, 2006), also observed with CB1/ligand coupling in human
neuroblastoma SH-SY5Y cells (Marini et al., 2009). The select
binding of CB2 is believed to be an ideal route and so compoundswith re-
strictive capacity to peripheral tissues and so unable to cross the BBB
(Pertwee, 2009) may minimize the psychoactive properties exhibited
with CB1 agonists. However, alkylamides (dodeca-2E,4E,8Z,10Z-
tetraenoicacidisobutylamide) have been shown to cross the BBB; none-
theless their poor binding affinity to CB1 might present a promising op-
tion for treating CB2 associated disorders. Furthermore, the observed
effects of the alkylamides hold additional implications, such as the treat-
ment of congestive heart failure, as an elevation of intracellular Ca+ ions
is known to effectuate a positive ionotropic effect. This effect parallels the
mode of action exhibited by the cardiac glycosides, digoxin and digitoxin,
that inhibit the target molecule, Na/K+ ATPase enzyme. Inhibition of this
enzyme causes an imbalance in the ratio of Na+ to K+ ions that results in
elevated intracellular Ca+ ions. When this occurs, there is a subsequent
increase in the strength of the heart muscles. This has implications for
the treatment of congestive heart failure. The elevation in Ca+ levels par-
allel the mode of action exhibited by the cardiac glycosides, digoxin and
digitoxin, that inhibit the targetmolecule, Na/K+ATPase enzyme. Inhibi-
tion of this enzyme causes an imbalance in the ratio of Na+ to K+ ions
that results in elevated intracellular Ca+ ions. When this occurs, there
is a subsequent increase in the strength of the heart muscles.
Alkylamide-basedmodulation of the ECS also demonstrated implications
for anti-inflammatory effects (Raduner et al., 2006) in addition to indi-
rect influence on the ECS through interfering with the bioavailability of
eCB precursors (Banni & Di Marzo, 2010; Di Marzo & Despres, 2009).
Another family of compoundswith promising ECSmediated efficacy
is terpenes. α,β-Amyrin, a pentacyclic triterpene exhibited CBmediated
anti-inflammatory and antinociceptive effects and the latter were com-
parable to synthetic molecules, ACEA and JWH-133 (da Silva et al.,
2011). While α,β-Amyrin modulated the activities of both CB1 and
CB2, α,β-Amyrin was 15,000 fold more selective for CB1 (da Silva et al.,
2011), 200–300 fold more potent than Δ9-THC (Chicca, Marazzi, &
Gertsch, 2012) and did not present with behavioral effects making
this phyCB an ideal smallmoleculewarranting further investigations es-
pecially in combination therapies. The terpene, β-caryophyllene of
Cannabis sativa is a selective agonist of CB2 receptors (Gertsch, 2008)that exerts anti-inflammatory and analgesic effects in addition to easing
neuropathic pain (Zimmer, Treschan, Meier, & Nosch, 2009). A recent
review highlights β-caryophyllene's multifaceted therapeutic effects
including its observed synergy with other GPCR signaling pathways
(μ-opioid receptor dependent pathways) strongly indicating the
value of this phyCB to treat ECS associated morbidities (Sharma et al.,
2016). The diterpene salvinorin has also confirmed effects from a
polypharmacological angle as it is a selective κOR GPCR agonist and
CB ligand (Fichna et al., 2009).
More recently, in vitro research shows the antiproliferative effects of
the flavonoid, quercitin, mediated by CB1 (Refolo et al., 2015). A review
by Guzman (2003) highlights the potential anticancer effects of select
cannabinoids, isolates from Cannabis sativa and a fairly recent review
(Chakravarti, Ravi, & Ganju, 2014) provides amore detailed representa-
tion of the efficacy of these isolates to treat cancer. On another note, in-
direct modulation of the ECS was observed in the presence of naturally
occurring quinoid terpenoids, pristimerin and euphol through revers-
ibly inhibiting the activity of the enzyme, monoacylglycerol lipase
(MAGL). For other phyCBs that exhibit efficacy through the CBs and
the ECS, see Table 2.4. Concluding remarks and future perspectives
CBs play an important role effectingmany biological switches and so
they are targets for treating autoimmune diseases (Cabral & Griffin-
Thomas, 2009), inflammatory and/or neuropathic pain (Guindon &
Hohmann, 2008), osteoporosis (Karsak et al., 2005), cancer (Velasco,
Sanchez, & Guzman, 2016) and most recently, diabetes (Lu, Dopart, &
Kendall, 2016; Vemuri, Janero, &Makriyannis, 2008). The latter is an in-
teresting tangent to the well-researched insulin-mediated signal trans-
duction pathway that has been explored for many decades but
continues to present challenges of drug resistance and toxicity
effects (Kooti, Farokhipour, Asadzadeh, Ashtary-Larky, & Asadi-
Samani, 2016). The treatment of diabetes through either the ECS or
the insulin-mediated signal transduction pathway holds promise to
treating diabetes associated comorbidities, cardiovascular andmetabol-
ic disorders, collectively known as the metabolic syndrome.
The transduction of signals through the CBs bymeans of endogenous
ligands has established a foundation for possible exogenousmodulators
that can mitigate disease initiation and progression. So far, agonists of
the CBs are theoretically important for ameliorating neurodegenerative
disorders, treating pain and many cancers and evidence of these exists
at various stages of research as discussed earlier. On the other hand, an-
tagonists have been shown to primarily play a role inweight loss, diabe-
tes and treating feeding disorders. Yet, the theory of these expectations
are not necessarily realised in clinical research and if they are, they are
usually accompanied by unbearable side-effects and thus the many
drug withdrawals. This is possibly due to the gross oversimplification
of the ECS which encompasses a myriad of factors that surround bioac-
tivity outcome. These factors include tissue locale, CB's shapeshifting
myriads, CBs' density and their coupling efficiencies, CBs' dimerization
with other GPCRs and protein receptors, and other CBs' direct and indi-
rect targets.
Both synthetic and natural ligands of the CBs have demonstrated
promising efficacy and indeed the lack of clinical applicability is congru-
ent to both types of exogenous CB ligands. For example, despite the
promising efficacy of Δ9-THC to treat various neurodegenerative disor-
ders (Scotter, Abood, & Glass, 2010) and oncology (Walsh, Nelson, &
Mahmoud, 2003), its psychoactive side-effects continue to be a
deterrent to its treatment of AD, ALS, HD and cancer. So currently,
Dronabinol, the international nonproprietary name of Δ9-THC is used
to treat anorexia in people with HIV/AIDS in addition to nausea and
vomiting in persons undergoing chemotherapy (Haney et al., 2007).
Rimonabant, the synCB antagonist that showed promising efficacy to
the treatment of diabetes and was therefore approved by the European
Union in 2006 was later discontinued from commercial markets and
clinical research because of grave risk of psychiatric disorders.
Indeed, natural products paved the way for the current understand-
ing of the ECS and their value in structural diversification, ECS signal
transduction pathway elucidation and the synthesis of CB ligands con-
tinue to steer future directional ECS research. But the efficacy of both
natural and synthetic compounds seems to lie in their specific associa-
tion with the CBs and CB associated targets and their concentration,
the latter confirming the theory of Paracelsus. This indeed requires
more mechanistic investigations in a systematic way in order to delin-
eate the mode of action of the phyCBs and synCBs. Understanding fur-
ther, the mechanism used by synthetic versus natural drugs to elicit
beneficial effects specifically through the various targets outlined in
Fig. 2 is paramount. One such example is the effects of allosterism on
the ECS' functionality aswas delineated for the synthetic allostericmod-
ulator, ORG27569. ORG27569 enhanced the current selective direct CB
agonists, competitive antagonists and enzyme inhibitors. The concept
of allosterism to provide an enriched landscape for novel therapeutics
is shared by Changeux & Christopoulos (2016). Further, delineating
the CB conformational states and their desensitization, internalization,
resensitization, and downregulation (Raehal & Bohn, 2014) regulated
through the β arrestins may be pivotal to advancing the development
of CB exogenous ligands with enhanced efficacy. What is now needed
is evidence of the clinical efficacy of CB induced β-arrestin modulation
that are aligned with the observed efficacy of combination therapies of
μORanalgesic,morphine and μORantagonists, naloxone andnaltrexone,
usually given minutes apart. These antagonists diminish β-arrestin re-
cruitment resulting in the improved analgesic properties of morphine
while endowing significantly reduced side-effects caused by morphine,
like nausea (Gan et al., 1997; Rebel, Sloan, & Andrykowski, 2009). The
role ofβ-arrestinmodulationwarrants further research in ECS associated
disorders and preclinical findings demonstrate the antinociceptive po-
tential of Δ9-THC in β-arrestin2-KO mice (Raehal & Bohn, 2014). None-
theless, alternatives to treat nausea and vomiting with reduced CNS
related side-effects exist like the class of setron (e.g. Ondansetron).
Crystal structures of the CBs are necessary and could assist in identi-
fying more neutral or peripherally exclusive drug leads especially in
light of the many drug withdrawals. Given the recent advance in CB1
crystal structure elucidation, advances in further delineating binding as-
sociations of the natural and synthetic leads to the CBswill be propelled
further, paving the way for maximizing potential synergism within
combination therapies. Understanding how the efficacy of one product
whether natural or synthetic, impacts another, in that, if it enhances/di-
minishes bioactivities of other eCBs and exogenous CBs may only be
achievedwith amore comprehensive overview of the ECS. Even though
significant strides have been made in this area, there remains much to
be uncovered, for example, other putative CBs like orphan GPR55 and
GPR18 receptors that are controlled by cannabinoid like molecules in
addition to their participatory role in the ECS (Haugh, Penman, Irving,
& Campbell, 2016). Additionally, there also remains much to be uncov-
ered about the G proteins and the modulatory effects of phyCBs com-
pared to synCBs with respect to the CB/G protein complexes.
Furthermore, findings suggest that particular G protein mutations are
more favorable to bind nonclassical cannabinoid ligands (Shim,
Bertalovitz, & Kendall, 2011) compared to classical ones. G proteinmod-
ulation seems to hold promise in cancer treatment and possibly preven-
tion (Fan et al., 2013), yet the precise mechanism of action especially in
relation to the ECS includingwhich of the numerous subunits under the
G protein family are impacted and how, remains unknown. Dated re-
search demonstrates the effects of phyCBs and synCBs on various G pro-
tein activation dependent and independent of CB activation. Overall, the
synCB, HU201was foundmore potent than the eCB, AEA and the phyCB,
Δ9-THC (Glass & Northup, 1999).
Finally, what is needed is a high-throughput systematic mechanism
for screening the phyCBs and their analogues and is discussed further in
the review article by Zhang and Xie (2012) that readily integrates notonly therapeutic signal transduction pathways but also relevant adverse
pathways in order to truly ascertain phyCBs that have novel therapeutic
actions not mirrored by synthetic drugs. The seven helical scaffolds of
the CBs warrant pharmacological assays that can compute biased re-
joinders and measured expression in chemical scaffolds to enhance bi-
ased effects. Classical in vitro assays are limiting yet efficient while
preclinical research findings contribute to clinical translation, although
limitations on efficiency and costs continue to be a challenge. Hence,
an in vitromethod that enables rapid results emblematic of clinical effi-
cacy taking into account age, inflammation, genetic and epigenetic al-
terations within the CBs and its targets is ideal though a momentous
task. Therefore organ-on-chip technology (van der Helm, van der
Meer, Eijkel, van den Berg, & Segerink, 2016) when fully streamlined
maybe an ideal route that will propel the development of phyCBs in
treating ECS associated morbidities.
5. Expert opinion by David Puett
This paper presents a comprehensive and critical timely overview of
cannabinoid receptors and the endogenous and exogenous ligands,
both synthetic and naturally occurring, that act via CB1 and CB2. These
receptors are members of the G protein-coupled receptor (GPCR)
superfamily that constitutes the largest gene family in the human ge-
nome, indeed with an estimated 800 members and accounting for ap-
proximately 1% of the total protein coding genes. The crystallographic
structures of several GPCRs, and most recently the CB1 as well as mem-
bers of the four families of the associatedG proteins, have been elucidat-
ed in recent years, thus facilitating detailed structure-function studies.
The review of signaling mechanisms presented by the authors and the
discussion of endocannabinoids set the stage nicely for the discussion
that follows on exogenous synthetic and naturally occurring ligands
that hold promise in treating a variety of disorders. The concluding sec-
tion outlines the importance of research on this topic and offers cogent
recommendations for advancement of the field. This paper will make a
timely and valuable contribution to the literature.
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